Difficulty: Medium
Average Score: 70%
Practice
A 36-year-old man with multiple medical problems including diabetes, hypertension, and morbid obesity is hospitalized for treatment of a vancomycin-resistant Enterobacter infection. Recent blood cultures are positive. He is given quinupristin/dalfopristin intravenously through the antecubital vein. Which of the following sequelae is most likely?
Correct answer
D
Rationale
In this scenario, the most likely sequelae of intravenous quinupristin/dalfopristin administration to the 36-year-old man with multiple medical problems is renal failure (Option D). Quinupristin/dalfopristin is associated with nephrotoxicity, particularly in patients with pre-existing renal impairment. The drug's metabolites can accumulate in renal failure, leading to further kidney damage.
Option A, Arthritis, is unlikely as quinupristin/dalfopristin is not commonly associated with joint inflammation. Option B, Hepatic dysfunction, is less likely as this drug is primarily metabolized in the liver and is not a common cause of significant hepatic impairment.
Muscle fatigue (Option C) can occur with quinupristin/dalfopristin use but is not the most likely sequelae in this case. Renal failure is a more severe and common complication associated with this drug.
Educationally, understanding the potential adverse effects of medications is crucial for healthcare providers to make informed decisions when treating patients, especially those with multiple comorbidities. Knowledge of drug pharmacology and side effect profiles helps in ensuring patient safety and effective management of complications. It underscores the importance of individualizing treatment regimens based on patient characteristics to minimize risks and optimize outcomes.
Option A, Arthritis, is unlikely as quinupristin/dalfopristin is not commonly associated with joint inflammation. Option B, Hepatic dysfunction, is less likely as this drug is primarily metabolized in the liver and is not a common cause of significant hepatic impairment.
Muscle fatigue (Option C) can occur with quinupristin/dalfopristin use but is not the most likely sequelae in this case. Renal failure is a more severe and common complication associated with this drug.
Educationally, understanding the potential adverse effects of medications is crucial for healthcare providers to make informed decisions when treating patients, especially those with multiple comorbidities. Knowledge of drug pharmacology and side effect profiles helps in ensuring patient safety and effective management of complications. It underscores the importance of individualizing treatment regimens based on patient characteristics to minimize risks and optimize outcomes.